Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441766 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
NCT00441766 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 213 participants.
The verdict
NCT00441766, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
Study Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts. Part A enrolled 213 pts dosed with either 3, 20, 60 mg AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 320 pts and dose with either 60, 100, 160 mg BID AGN 203818 or placebo over 12 week treatment duration.
Interventions
- DRUG placebo
- DRUG AGN 203818
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441766
The ClinicalTrials.gov registry entry for NCT00441766 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00441766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00441766 about?
NCT00441766 is a clinical study titled "Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain". This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts. Part A enrolled 213 pts dosed with either 3, 20, 60 mg AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 3...
What is the current status of trial NCT00441766?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2007-03. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00441766?
The interventions under investigation include: placebo (DRUG), AGN 203818 (DRUG).
Who is sponsoring clinical trial NCT00441766?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.